Authentication and characterisation of a new oesophageal adenocarcinoma cell line : MFD-1 by Garcia, Edwin et al.
1Scientific RepoRts | 6:32417 | DOI: 10.1038/srep32417
www.nature.com/scientificreports
Authentication and 
characterisation of a new 
oesophageal adenocarcinoma  
cell line: MFD-1
Edwin Garcia1, Annette Hayden1, Charles Birts1, Edward Britton2, Andrew Cowie1, 
Karen Pickard1, Massimiliano Mellone1, Clarisa Choh1, Mathieu Derouet1, Patrick Duriez1, 
Fergus Noble1, Michael J. White1, John N. Primrose1, Jonathan C. Strefford1, 
Matthew Rose-Zerilli1, Gareth J. Thomas1, Yeng Ang2, Andrew D. Sharrocks2, 
Rebecca C. Fitzgerald3, Timothy J. Underwood1 & the OCCAMS consortium†
New biological tools are required to understand the functional significance of genetic events revealed 
by whole genome sequencing (WGS) studies in oesophageal adenocarcinoma (OAC). The MFD-1 cell 
line was isolated from a 55-year-old male with OAC without recombinant-DNA transformation. Somatic 
genetic variations from MFD-1, tumour, normal oesophagus, and leucocytes were analysed with SNP6. 
WGS was performed in tumour and leucocytes. RNAseq was performed in MFD-1, and two classic OAC 
cell lines FLO1 and OE33. Transposase-accessible chromatin sequencing (ATAC-seq) was performed in 
MFD-1, OE33, and non-neoplastic HET1A cells. Functional studies were performed. MFD-1 had a high 
SNP genotype concordance with matched germline/tumour. Parental tumour and MFD-1 carried four 
somatically acquired mutations in three recurrent mutated genes in OAC: TP53, ABCB1 and SEMA5A, 
not present in FLO-1 or OE33. MFD-1 displayed high expression of epithelial and glandular markers and 
a unique fingerprint of open chromatin. MFD-1 was tumorigenic in SCID mouse and proliferative and 
invasive in 3D cultures. The clinical utility of whole genome sequencing projects will be delivered using 
accurate model systems to develop molecular-phenotype therapeutics. We have described the first such 
system to arise from the oesophageal International Cancer Genome Consortium project.
Oesophageal cancer is hard to treat. Patients typically present with late-stage disease and respond poorly to con-
ventional anti-cancer therapies1. In the case of oesophageal adenocarcinoma (OAC) rates of diagnosis and death 
run roughly parallel and there have been few improvements in outcomes in the last 30 years2.
Recent efforts have been directed towards understanding the genetic landscape of OAC with a view to the 
identification of potentially targetable driver mutations. These studies have revealed the complexity of the 
genomic aberrations in OAC. The progression from Barrett’s Oesophagus (BE), the only known precursor lesion 
from OAC, to invasive cancer is characterised by early chromosomal instability, probably due to p53 loss, often 
including genome doubling and a high frequency of chromothripsis events resulting in considerable genetic 
diversity followed by a later acquisition of driver mutations at sub-clonal frequencies3–5. By tracking the genomic 
evolution of OAC through neoadjuvant chemotherapy (NAC) treatment and surgical resection, Murugaesu et al. 
have further revealed an association between high intratumour heterogeneity and poor response to NAC6. Such 
complexity makes the identification of tractable therapeutic targets difficult and necessitates the development of 
in-vitro models that represent the mutational burden of the primary tumour.
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Unfortunately there is a paucity of such tools with which to study OAC. This lack of suitable preclinical models 
is frustrating efforts to understand both the basic biology of the transition from BE to OAC and the develop-
ment of novel therapies for established cancer7. BE is confined to humans and some primates8 but the logistics 
of performing research in large mammals and the anatomical interspecies differences in the oesophago-gastric 
junction between humans and rodents has limited representative animal modelling9,10. Research on OAC is there-
fore dependant on a very small set of established cell lines, with little known about the genomic landscape of the 
tumour of origin or how representative the cell lines are of the genetic aberrations within the primary cancer. In 
a world-wide effort to validate the authenticity of 13 of the 14 OAC cell lines available in 2010, Boonstra et al. 
found that 3 frequently used lines originated from other tissues (lung cancer, colorectal cancer, gastric cancer)11. 
Over 100 publications, three National Institute of Health grants and 11 US patents have been founded on these 
cell lines. These concerns are not confined to oesophageal cancer research. When the National Cancer Institute’s 
Developmental Therapeutics Program (DTP) panel of 60 cancer cell lines derived from nine different tumour 
types was assessed for relevance in the study of clinical multidrug resistance (MDR) mechanisms it was found that 
the cell lines bore more resemblance to each other, regardless of the tissue of origin, than to the clinical samples 
they were supposed to model12. In OAC, even for the verified cell lines that are currently used, no data is available 
for the matched primary tissue.
In an attempt to address these weaknesses a number of groups have used alternative strategies for the estab-
lishment of in-vitro models in OAC, such as the immortalisation and malignant transformation of Barrett’s meta-
plastic epithelial cells by disrupting key signalling pathways and telomerase overexpression13. New, well-described 
and authenticated, cell lines derived from OAC without any in-vitro modification are valuable tools, such as the 
recently introduced OANC114,15. But these cell lines may or may not be representative of the mutational profile of 
cells driving the malignancy in vivo16.
Using complementary genome wide analysis techniques including whole genome sequencing and geno-
typing of tumour biopsy and matched normal tissue from the oesophagus and peripheral blood we describe 
the establishment of a new model system in OAC (MFD-1) that retains the mutational profile of the primary 
tumour, including the identification of novel mutations in recognised cancer associated genes in OAC. Using a 
whole-transcriptome approach we compare and contrast the expression of recognised OAC associated genes in 
MFD-1 with established cell lines commonly used to study OAC. We show that MFD-1 is a highly representative 
model of OAC, it is stable over time and retains the ability to form tumours in xenograft models that respond to 
microenvironmental stimuli.
Materials and Methods
Ethics. The study was approved by the Southampton and South West Hampshire Research Ethics Committee 
(Oesophagus: molecular, cellular and immunological assessment. LREC number: 09/H0504/66). The methods 
were carried out in accordance with the approved guidelines and written informed consent was obtained prior 
to the study.
Patient clinicopathological chacteristics. The MFD-1 cell line was derived from a 55 year-old white 
male with locally invasive adenocarcinoma of the oesophagus clinically and radiologically (CT, PET & EUS) 
staged as T3N1M017. The patient was treated with 3 cycles of neoadjuvant chemotherapy (Epirubicin, Oxaliplatin 
and Capecitabine) prior to oesophagectomy. Histopathological analysis revealed a ypT4N3(15/26)M0 tumour 
with complete microscopic surgical resection (R0). The Mandard tumour regression grade (TRG)1,18 score was 5. 
Barrett’s oesophagus was not observed in the resection specimen. The patient died seven months after surgery 
from recurrent disease.
Isolation of Tumour cells and establishment of the OAC cell line. The specimen was transferred 
directly from the operating theatre to the research laboratory in complete DMEM media (10% FBS, Penicillin 
streptomycin) on ice, washed with 10 ml of phosphate buffered saline 3 times and minced with a scalpel to reach 
approximately 3 mm3 pieces that were subsequently digested with trypsin-EDTA (Sigma, Missouri-USA) at 37 °C 
in a 5% humidified atmosphere for 30 minutes. Undigested tissues and debris were removed by sedimentation and 
the clear supernatant was collected and spun at 600 g for 5 minutes. Cell pellets were cultured in complete DMEM 
under standard cell culture incubation conditions. The cell line has been deposited in the European Collection 
of Authenticated Cell Cultures (ECACC), a standard resource for the academic research community. Individual 
researchers wishing to verify the findings in this study can also approach the corresponding author directly to 
obtain frozen cell stocks.
SNP6 array genotyping. Genotyping of genomic DNA from peripheral blood mononuclear cells (PBMC), 
tumour and adjacent normal squamous oesophageal epithelium, and two early passages of the MFD-1 cell line 
(P1 & P4) were performed according to manufacturer recommendations (Affymetrix, California USA)19. The 
SNP6 array contained 906,000 probes for the genotyping of SNPs and 946,000 probes for the genotyping of 
non-polymorphic copy number. Affymetrix CEL files were analysed using the tool PICNIC20 (predicting abso-
lute allele copy number variation with microarray cancer data). Data are deposited with ArrayExpress (Accession 
number E-MTAB-4590).
Whole genome sequencing. Whole genome sequencing (WGS) from snap-frozen oesophageal tumour tis-
sue and germline nucleic acids isolated from peripheral blood mononuclear cells (PBMC) was performed as part 
of the International Cancer Genome Consortium project and OCCAMS consortium as previously described4,21. 
Filtered read sequences were mapped to the human reference genome (GRCh37) using Burrows-Wheeler 
Alignment (BWA) (Accession number E-MTAB-4600). In the matched tumour/germline samples, somatic 
acquired mutation identification was performed using a Bayesian algorithm implemented in the tool Seurat22. 
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Functional annotation of identified somatic mutations was performed with the tool SnpEff 23. Copy Number 
Variation (CNV) in matched pairs WGS files was determined with the tool Control-FREEC24.
RNAseq. Cell lines were kept under standard cell culture conditions FLO1 and MFD1 were cultured in 
DMEM supplemented with 10% FBS and antibiotics. OE33 were cultured in RPMI complete media 10% and 
antibiotics. Cells seeded in 10 cm2 dishes, three replicates for each cell line were grown for 72 hours. RNA extrac-
tion was performed following manufacturer recommendations (Reliaprep, Promega). RNA QC and libraries were 
processed by Cambridge Genomics Service in a NextSeq500 Illumina Platform. Approximately 20 million reads 
library per replicate were mapped using Tophat against hg1925. Reads were transformed to absolute counts using 
default settings in HTseq26, relative expression between samples and within replicates are displayed as logarithm-
2Counts per Million (logCPM) following the algorithms implemented in EdgeR27. For the RNAseq analysis reads 
were first trimmed to remove Illumina adapter sequence using trimmomatic 0.32 (Bolger et al.28). Trimmed reads 
were aligned to the ensemble transcription (release 72) human genome 19 (hg19) using the RNA-Star aligner (ver-
sion 2.3.0e) (Dobin et al., 2013). Differential expression analysis was carried out using Cuffdiff (Trapnell et al.25) 
in default settings.
Assessment of Clonality in MFD-1. Cells were seeded at a density of 1000 cells in 10 ml of DMEM com-
plete media in 10 cm2 petri dishes and maintained under standard cell culture conditions until colonies were 
observed. Colonies were picked using a ring cloning method29 and transferred to a new container for further 
expansion. Mutations identified in the parent cell line were screened in three colonies using Sanger sequencing.
Organotypic culture. 3D oesophageal organotypic cultures were performed as previously described15,30,31. 
The 3D cultures were kept under incubation for 14 days, then harvested, fixed in 4% paraformaldehyde and sub-
mitted for histopathological processing and Haematoxylin and Eosin staining.
Tumour xenografts. Female SCID/NOD mice were inoculated with epithelial cells (4 million) alone or 
epithelial cells (4 million) embedded with normal or cancer associated fibroblasts (2 million). Inoculation of 
cells proceeded as follows: In the left flank epithelial cells only, in the middle epithelial cells mixed with normal 
oesophageal fibroblasts and in the right flank epithelial cells mixed with cancer associated fibroblast from the 
oesophagus15. Cells were inoculated in a volume of 150 μl PBS. OE33 and FLO-1 cells were used as controls. Mice 
were culled at day 64 post inoculation, tumours were measured and fixed in paraformaldehyde for histology 
documentation.
Transposase-accessible chromatin with highthroughput-sequencing (ATAC-seq). ATAC-seq 
reports on the accessible regions of the genome which are thought to represent areas of “active” chromatin32,33. Of 
the nuclei from fifty thousand cells from MFD-1, OE33 and the non-neoplastic oesophageal cell line HET1A was 
the input material in an ATAC-seq protocol32,33 which involves treatment of a nucleic fraction with hyperactive 
Tn5 transposase that simultaneously cut and ligate adapters. This was followed by 12 cycles of PCR amplification 
and purification of amplified products was made with 1.8 volumes of SPRI beads (Ampure XL) following man-
ufacturer recommendations. Library QC was performed with the qubit assay. One microliter of the library was 
used on the TapeStation D1000 screentapes. Library stocks were normalized to 0.5 pg/μl and analysed by qPCR 
using the Illumina quantification kit (KAPA Biosystems) in triplicate. The library concentration was calculated 
using the equation in the KAPA kit instructions which uses the size of the library as calculated by the Tapestation, 
and multiplied by the dilution factor used to make a final 10 nM stock. ATAC-seq libraries (12 pM) were loaded 
onto a HiSeq-2500 with a 1% PhiX spike on a Paired End 101 × 101, dual indexed run.
ATAC-seq data analysis. Raw fastq files were de-multiplexed and trimmed using Trimmomatic (version 
0.32)28. Trimmed reads were aligned to hg19 using Bowtie234 with flags –X2000 –dovetail. Mapped reads were 
filtered to remove unpaired and low mapping quality reads (< q30) using samtools35. Optical duplicates were 
removed with Picard and finally reads mapping to encode blacklist regions were removed36. Next, peak calling 
was carried out using MACS237 using flags -q 0.01 -g hs -f BAM –nomodel –shift -75 –extsize 150 -B –SPMR. 
The shift and extend is to focus the peak calling on Tn5 cleavage sites (5′ end of the read). Differentially acces-
sible regions were identified by merging bam files of the conditions to be compared and recalling peaks using 
MACS237. A 500 bp window around the summit of the top 50,000 regions identified by MACS2 were analysed for 
differential accessibility using Cufflinks25. Normalised cleavage events across the differentially accessible regions 
were then counted using HOMER38. Heatmaps were ploted with the tool GENE-E (BROAD Institute) De novo 
motif discovery was carried out in HOMER38 with flag –cpg for background normalisation. Data are deposited 
with ArrayExpress (Accession number E-MTAB-4209).
Results
Genetic confirmation of MFD-1 derivation from parent tumour tissue. Analysis of genotypic 
and Copy Number Variation (CNV) data from the SNP6 platform confirmed the shared, parental origins of 
DNA from PBMCs, normal oesophagus, oesophageal cancer and two passages (P1 & P4) of the MFD-1 cell line 
(Fig. 1a–c). To allow visualisation of the size and location of genomic CNVs across samples data from the SNP6 
platform were combined with WGS from the parent tumour and represented diagrammatically using Circos 
plots39 (Fig. 1b,c). Analysis of the SNP6 data with the PICNIC algorithm showed that the MFD-1 cell line is likely 
to harbour a triploid chromosome complement (Supplementary Figure 1).
Identification of somatic acquired mutations in parent tumour tissue using WGS. Using a 
Bayesian algorithm in matched paired genomes22 a somatic single nucleotide variant (SNV) was observed every 
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19,932 bases in the parent tumour, in keeping with the high mutational burden of OAC4. The number of transitions 
and transversions were evenly distributed in this tumour with 73,723 and 81,860 respectively for a ratio TS/TV 
of 0.906 (Fig. 2a) and most SNVs were found in non-coding regions (Fig. 2b). For the purposes of MFD-1 vali-
dation, genes with frequent and recurrent mutations in oesophageal adenocarcinoma, as determined by the most 
Figure 1. Whole genome SNP genotyping and landscape of copy number variations in normal, tumour 
and MFD-1 genome. (a) Genetic material extracted from germ line, tumour, adjacent normal tissue, and 
two passages of the MFD-1 cell lines were analysed with the SNP6 array platform. The maximum number 
of SNPs with identical genotype calls was observed between genomic material isolated from normal tissue 
and that extracted from peripheral blood cells reaching 771,946 for a 99% concordance rate (Genomic DNA 
from PBMCs), (b,c) Circos plots with Genomic CNVs on the inner 4 rings (Black: genomic material from 
PBMCs, Green: Genomic material from normal oesophagus, Blue: genomic material from tumour, Orange: 
genomic material from MFD-1) and WGS data from the parent tumour on the outer ring. (b) Whole genome 
(c) chromosomes 2, 8, 11, 12, 15, 17, X and Y. CNV comparison between germ-line, tumour and cell line DNA 
confirms derivation of MFD-1 from the parent tumour. For example, the CNV plot of MFD-1 shows a loss of 
the Y chromosome and a duplication of the X chromosome that was also revealed by WGS in tumour DNA. The 
MFD-1 cell line retains CNV from germline DNA and tumour DNA. CNVs found in the normal genome, such 
as the gain with a scale of 4 on chromosome 2 at 95 cM is readily observed in all of the genomes under analysis, 
acting as a fingerprint of identity. A homozygous deletion is observed in genome isolated from PMBC on 
chromosome 8 at 45 cM, this mark is preserved across the genomes under analysis. On chromosome 16 at 20 cM 
there is a gain CNV in the tumour tissue that is not found in the normal genome (PMBC or adjacent normal 
tissue DNA) but is readily observed in the MFD-1 cell line.
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recent WGS studies3,4, were assessed in the dataset of single nucleotide acquired mutations identified in the parent 
tumour. Of 33 candidate genes, four were found to have non-synonymous acquired mutations with a potential 
high impact on product function in the parent tumour. These genes were ABCB1, DOCK2, SEMA5A and TP53 
(Fig. 2c) and ABCB1 contained 2 separate non-synonymous coding mutations. Furthermore these genes are in 
regions with major structural abnormalities revealed by the CNV annotation. For example, the ABCB1 gene is in 
a region with a copy number state of four, whilst DOCK2, SEMA5A and TP53 loci are in regions subjected to loss 
of heterozygosity in a copy neutral state which translates to a duplication of the mutant allele (Fig. 2c).
Genotyping of acquired mutations in MFD-1. To confirm the retention of these potentially important 
mutations in MFD-1 genomic DNA from the MFD-1 cell line and three derived clones obtained by single cell 
dilution ring cloning method29 was genotyped by Sanger sequencing at the 5 acquired mutations identified by 
WGS in the tumour. Four of the five somatic acquired mutations identified by WGS in the parent tumour tissue 
were found in the MFD-1 cell line and the genotype calls were identical in the parent MFD-1 cell line and derived 
clones (Fig. 3a). The DOCK2 somatic acquired mutation on chromosome 5 at genomic position 169135201, the 
mutant allele G, runs at a frequency of 10% of the reads by WGS but the cell line is homozygous wild type for the 
reference allele A. Genotyping of the ABCB1 somatic acquired mutation in the cell line or derived clones is con-
sistent with a heterozygous state. This gene on chromosome 7 carries two somatic acquired mutations at positions 
87179790 and 87150168 with a frequency in the tumour of 26% and 30% of the WGS reads respectively (Fig. 3a). 
TP53 on chromosome 17 carries a mutation at position 7577120 found in 41% of the WGS reads in the tumour, 
the MFD-1 parent line and derived clones are homozygote mutant. Finally the SEMA5A gene on chromosome 5 
at position 9190519 carries a mutation in the tumour found in 35% of the WGS reads whilst the MFD-1 parent 
cell line and clones are homozygotes mutant (Fig. 3a). By comparison two of the most commonly used OAC cell 
lines in current research, FLO1 and OE33, do not carry these mutations (Data not shown).
Comparative analysis of gene expression between OAC cell lines using RNA-seq. Previous 
reports have documented the use of various platforms to confirm expression of gene products related to the 
expected morphology of OAC cells. For instance, verification of the OANC1 cell line was performed using 
immunohistochemistry for columnar (CK18), glandular (CK7) and intestinal (CDX2, SOX9, villin) markers in 
xenografts. In keeping with the genome wide approach used to document somatic mutations in the MFD-1 par-
ent tumour, we performed RNA-seq of MFD-1, OE33 and FLO1 in culture to compare global gene expression 
(Fig. 3b) (the authenticity of OE33 and FLO1 was first confirmed by short tandem repeat analysis; data not 
shown). MFD-1 was confirmed to express CK18 (KRT18), CK7 (KRT7), SOX9 and Villin in high abundance. 
Figure 2. Somatic acquired mutations in tumour and copy number in MFD-1 . (a) Transition and 
transversion frequency of somatic acquired mutations in tumour tissue. (b) Histogram of somatic acquired 
mutations in tumour. A left skew histogram shows the most common mutations are in non-coding region and 
the less common but functionally relevant mutations are in regions around or within genes. (c) Recurrent and 
frequent genes mutated in oesophageal adenocarcinoma were assessed in the dataset of acquired mutations 
catalogued in the tumour. Genomic regions and frequency of somatic acquired mutations is shown for each 
gene. In this panel four genes have non-synonymous acquired mutations. The ABCB1 carries two whilst TP53, 
DOCK2 and SEMA5A carry one. The lower frame shows MFD-1 copy number status revealed by SNP-6 
array platform and the minor allele frequency. The colour code represents the aneuploidy status with yellow 
indicating loss of heterozygosity, red homozygous deletion and blue copy number gain. The ABCB1 has a 
copy number state of 4 compatible with amplification whilst the TP53, SEMA5A and DOCK2 shows loss of 
heterozygosity with a minor allele frequency of zero and duplication of a mutant allele which translate as a copy 
number of 2. This is suggestive of loss of heterozygosity in a copy neutral state.
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CDX2 was also expressed but at lower levels when compared to OE33 and FLO1. FLO1 appeared to have rela-
tively little expression of mRNA coding for cytokeratins, except CK18 (KRT18) compared to OE33 and MFD-1 
(Fig. 3b). This relative lack of expression was confirmed at the protein level using a pan-CK antibody in Western 
blot (Fig. 3c). Interestingly FLO1 showed very low expression of EpCAM mRNA in contrast to OE33 and MFD-1 
and the majority of primary oesophageal tumours. EpCAM expression at the cell membrane was confirmed in 
MFD-1 by flow cytometry (Fig. 3d). Integrity of expression of components the TGF family, used previously to 
authenticate another OAC line, SK-GT-4, was confirmed in all 3 cell lines (Fig. 3b, grey labels)
Sixteen of the 33 recurrently mutated genes in OAC had detectable mRNA expression in the 3 cell lines studied 
(Fig. 3b). In the MFD-1 cell line there was no expression of CDKN2A, consistent with a homozygous deletion at 
chromosome 9 in the SNP6 array data (Figs 3b and 1b). MFD-1 was the only cell line of those tested to express 
both SEMA5A and ABCB1 (Fig. 3b).
ATAC-seq analysis of the open accessible chromatin landscape of MFD-1 cells. A second 
approach to characterise the MFD-1 cell line was the assay for transposase-accessible chromatin using sequenc-
ing (ATAC-seq) analysis32,33. This technique reports on the accessible regions of the genome, which are thought to 
represent areas of “active” chromatin. MFD-1 was compared directly with OE33 and not FLO1, as FLO1 had been 
Figure 3. Selected validation of the mutation and expression profile of MFD-1 using multiple platforms. 
(a) Sequencing of genomic DNA from the MFD-1 cell line. PCR primers designed ~250 bp around the mutation 
were created at the following positions: ABCB1 (Chr7: 87179790 and 87150168); DOCK2: Chr5: 169135201; 
TP53: Chr17: 7577120; SEMA5A: Chr5: 9190519. The mutant allele is highlighted in red. The sequence depth 
in the germline and tumour tissue, the frequency observed for the mutant allele in NGS reads, the sequence 
adjacent to the observed mutation and the Ensemble identification reference is presented. The MFD1 cell line 
is heterozygote at two somatic acquired mutations on the ABCB1 gene, homozygote wild-type in the DOCK2 
gene, and homozygote mutant in the TP53 and SEMA5A gene. (b) Expression profiles shown as logCPM in 
epithelial markers and common recurrent genes in OAC. Dark blue counts not found in RNAseq dataset.  
(c) Pan cytokeratin western blot in lysates from OE33, FLO-1, MFD-1 and two Cancer associated fibroblast.  
(d) EPCAM (CD326) stained using flow cytometry in MFD-1.
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shown to express few oesophageal related epithelial markers (Fig. 3b,c). First we identified all of the genes that 
were expressed to significantly higher levels in MFD-1 compared to OE33 cells (Fig. 4a, top). Next we performed 
ATAC-seq on MFD-1 and OE33 cells and extracted the chromatin accessibility data (transposase cut counts) 
around the transcription start sites (TSS) of the genes showing elevated mRNA expression in MFD-1 compared to 
OE33 cells. The distribution of cut count densities showed that the chromatin accessibility around these genes was 
significantly higher in MFD1 cells (Fig. 4a, bottom), in keeping with the notion that ATAC-seq reports on “active 
chromatin”. Next, we investigated which regions are more open in cancer cells and whether these differed between 
MFD1 and OE33 OAC cell lines. We compared the ATAC-seq signals in MFD-1 and OE33 OAC cells to HET1A 
cells, which were derived from non-cancerous oesophageal tissue. We identified two classes of regions, which 
showed > 3 fold changes in chromatin accessibility which were either higher (open in MFD-1) or lower (open in 
HET1A) in MFD-1 compared to HET1A cells (Fig. 4b). While MFD1 cells showed clear differences to the HET1A 
cells, OE33 cells showed an intermediate pattern, demonstrating the heterogeneity between these OAC-derived 
cell types. For example, the KAT6A promoter is more open specifically in MFD-1 cells (Fig. 4c, top) although at 
other loci, exemplified by the KRT8 gene, the chromatin associated with the TSS is more open in both MFD-1 and 
OE33 cancer cell lines compared to HET1A cells (Fig. 4c, bottom). These results are in keeping with the different 
gene expression profiles exhibited by these cells (Fig. 3b). To gain potential insights into the regulatory processes 
that are altered in MFD-1 cells, we searched for over-represented transcription factor binding motifs within 
the regions of chromatin exhibiting differential accessibility. In regions of chromatin activated in MFD1 cells, 
Figure 4. Open chromatin regions in MFD-1 cells. (a) RNA-seq analysis (top) of genes differentially 
expressed to higher levels in MFD-1 compared to OE33 cells (> 3 fold change; P-value < 0.01). Each column 
represents one biological replicate. Data are row Z-normalised. The corresponding ATAC-seq signal in a 700 bp 
window around the TSS (− 500 to + 200 bp) of this cohort of genes in each cell line is shown as a boxplot of 
cut count densities (bottom). ***P-value < 0.05 (2 × 10−13). (b) ATAC-seq analysis showing the cut counts in 
regions showing differential accessibility (> 3 fold; P-value < 0.05) between MFD-1 and HET1A cells. Data are 
shown for MFD-1, OE33 and HET1A cells and grouped according to being more open in MFD-1 or HET1A 
cells. (c) UCSC genome browser tracks showing ATAC-seq cleavage data associated with the KAT6A (top) 
and KRT8 (bottom) loci in HET1A, OE33 and MFD-1 cells. Regions of open chromatin associated with the 
TSS (arrows) are boxed. (d) De novo motif discovery of transcription factor binding sites over-represented in 
the regions that are either open in MFD-1 cells (top) of MET1A cells (bottom). (e) GO term analysis of genes 
associated with a TSS showing changes (> 3 fold) in open chromatin in MFD-1 compared to HET1A cells. The 
most highly significant terms associated with disease Ontology are shown.
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motifs recognised by CTCF, NFY, Meis3 and Nrf2 were identified (Fig. 4d, top). In contrast, in chromatin regions 
showing reduced accessibility in MFD-1 cells and hence potentially lower activity, a different set of motifs were 
identified with AP-1 figuring most prominently among these (Fig. 4d, bottom). Thus regulatory events controlled 
by different transcription factors are likely important determinants of the gene expression programmes in MFD-1 
and HET1A cells. Interestingly, Gene Ontology analysis of the genes associated with the regulatory regions exhib-
iting differential accessibility (either increased or decreased) in MFD-1 cells showed enrichments for a large 
number of terms associated with cancer, including several epithelial cancers and GI tract neoplasms (Fig. 4e).
In vitro and in vivo analysis of MFD-1 as a model OAC system. To enable the rational design and 
testing of new therapeutic options for OAC new model systems such as MFD-1 need not only to represent the 
parent tumour at a genetic level, but furthermore recapitulate tumour growth in vivo and respond to microenvi-
ronmental signals that are increasingly recognised as determinants of cancer outcome15. MFD-1 was implanted 
in SCID mice alone (Fig. 5a) or in combination with normal oesophageal fibroblasts (Fig. 5b) or cancer associated 
fibroblasts (CAF) (Fig. 5c). In keeping with our previous findings in OAC15, when MFD-1 cells were combined 
with CAF xenograft tumours grew more quickly and to a larger size. When compared by routine H&E histology, 
the CAF containing tumours shared a similar morphology to the parent tumour (Fig. 5d–f) and were proliferative 
(Fig. 5g). Of note, the established OAC cell lines FLO1 and OE33 were implanted in an identical way in SCID 
mice in the same experiment; OE33 was non-tumourigenic under all conditions and FLO1 only formed tumours 
when combined with CAF, suggesting that MFD-1 is a more representative line for the invasive OAC phenotype.
We have previously demonstrated that selected OAC cell lines are invasive in a range of in vitro assays in 
response to microenvironmental stimuli15. We therefore tested MFD-1 using these assays. MFD-1 has been 
maintained under routine culture conditions for > 35 passages and retains characteristic morphological features 
(Fig. 5h). MFD-1 was invasive in 3D organotypic culture (Fig. 5i) and in Transwell invasion assays (data not 
shown). The somatic acquired mutations identified in TP53 and SEMA5A in MFD-1 (Fig. 3a) were present in the 
explanted xenografts confirming the cell line of origin (data not shown).
Figure 5. MFD-1 is tumour forming in SCID mouse. (a) MFD-1 cell line tumour in SCID mouse 4X (b) 
Tumour in SCID mouse from MFD-1 cells implanted with Normal oesophageal fibroblast 2X. (c) Tumour in 
SCID mouse from MFD-1 cells implanted with Cancer Associated Fibroblast (CAFs) 2X (d) Tumour H&E from 
case 4X (e) Tumour H&E from case 10X (f) Tumour in SCID mouse from MFD-1 cells implanted with Cancer 
Associated Fibroblast 10X (g) KI-67 of tumour in SCID mouse from MFD-1 cells implanted with CAFs 4X (h) 
MFD-1 cell line morphology under live microscopy 4X (i) MFD-1 in 3D cultures.
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Discussion
Research in OAC is hampered by a lack of pre-clinical models. This deficiency is frustrating efforts to under-
stand the basic biology of progression to OAC and the development of novel therapies for established cancer7. 
Improved understanding of the human genome40 has suggested a need for therapeutic agents targeting specific 
driver mutations. However, standard cell-lines match patient tumours poorly at a molecular level12 and do not 
fully recapitulate clinical drug responsiveness41; this has led to derivation of cells in vitro as primary cell-lines42,43 
or organoids44, or as patient-derived xenografts (PDXs)43,45–48. Such cells are urgently required for testing tar-
geted agents for treatment of OAC which is currently dependent on a small set of historic cell-lines. Here, we 
have described the first fully-characterised system (MFD-1) to arise from the oesophageal International Cancer 
Genome Consortium project and confirmed that it represents an invasive tumour model containing somatic 
mutations in genes known to be important in OAC biology that correspond to mutations in the parent tumour. 
We also offer further characterisation of two commonly used historical lines, OE33 and FLO1.
The majority of cell lines currently used in OAC research are decades old and were not subjected to the kind 
of detailed genetic authentication that current technologies make possible. For example OE33 was derived from 
a stage IIa Barrett’s cancer in 1996 and was subjected to karyotyping and cell surface antigen phenotyping, but no 
analysis of the primary tumour was presented, so the research community cannot know if the mutational burden 
of OE33 is representative of the tumour of origin49. Subsequent short tandem repeat (STR) comparison of OE33 
with the tumour of origin taken from formalin fixed paraffin embedded tissue has confirmed the authenticity of 
current OE33 cell stocks, but no genome wide analysis of mutational status has been performed11. Similar prob-
lems exist for all historic OAC cell lines. More recently Clemons and colleagues developed the OANC1 cell line14. 
Authenticity was confirmed by STR comparing the cell line and tumour of origin at 16 loci and targeted deep 
sequencing of 48 cancer related genes was performed, but only in the cell line. OANC1 is a valuable new addition 
for OAC researchers, however it may represent a “non-classical” OAC as it was derived from a 44-year-old patient 
and more information about the tumour of origin is required.
By contrast, the strength of the current work is that we have used multiple genome-wide platforms (WGS, SNP 
arrays, ATAC-seq and RNA-seq) in the primary tumour and the MFD-1 cell line to confirm the tissue of origin 
and to accurately document somatic mutations that can be further tested as potential tractable targets. Our initial 
analysis has concentrated on a panel of genes commonly mutated in OAC constructed by synthesizing data from 
the WGS studies described by Dulak3 and Weaver4, but this does not preclude future interrogation of the data as 
new targets are discovered.
We describe 5 mutations in 4 genes (ABCB1, DOCK2, SEMA5A and TP53) with relevance to OAC found 
in the parent tumour by WGS. Interestingly, the mutation observed in the lowest number of reads from the 
WGS data (DOCK2, mutant allele 10%) is homozygous wild-type in MFD-1, suggesting that the cell line is likely 
derived from the dominant clone in the tumour. The finding of a mutation in TP53 that has been extensively 
documented in OAC suggests that MFD-1 is representative of primary OAC tumours. The mutations in ABCB1 
and SEMA5A described here have not been previously reported in oesophageal cancer. Importantly, the products 
of these genes are expressed in MFD-1 making the cell line a useful model to study the biological effects of these 
mutations. ABCB1 encodes one of a family of ATP-binding cassette membrane transporters that efflux many 
chemically diverse compounds across the plasma membrane. These transporters are implicated in the devel-
opment of multidrug resistance in cancer cells treated with chemotherapy (reviewed in ref. 50). SEMA5A is a 
Semaphorin important in neuronal development that has recently been implicated in cancer development by 
influencing angiogenesis, tumour growth and metastasis (reviewed in ref. 51). The coexistence of mutations in 
SEMA5A and ABCB1 and the expression of both genes together in MFD-1 is of particular relevance because 
mutations in SEMA5A and ABCB1 were the only mutations found to co-occur more often than would be expected 
by chance in a cohort of 112 cases (P = 0.0021) of OAC by Weaver et.al, but the reasons for this association remain 
unclear4. In addition, the ABCB1 mutations may indicate a potential mechanism for chemotherapy resistance that 
was observed in the primary tumour. None of these mutations were found in OE33 or FLO1 and neither of these 
lines express ABCB1 and SEMA5A together. MFD-1 was generated from a tumour in a patient who had been 
treated with neoadjuvant chemotherapy. This leads to the potential that some of the mutations in MFD-1 may 
be chemotherapy induced, however the frequency of mutations observed in SEMA5A and ABCB1 in previous 
studies of chemotherapy naïve OAC point to these mutations being tumour specific.
MFD-1 is tumourigenic in SCID mice. This adds substantially to the utility of MFD-1 as a pre-clinical model 
of OAC and enables complex experiments that may include other constituents of the tumour microenviron-
ment and/or manipulation of the host organism to mimic human treatments, such as novel CAF targeted agents 
or combination therapies. Similarly to the results reported by Clemons et al.14 we found that FLO1 and OE33 
are poorly tumourigenic in SCID mice, this is somewhat surprising given that OE33 is one of the most com-
monly used OAC cell lines in xenograft experiments, however these findings reinforce the tumourigenic nature 
of MFD-1.
MFD-1 is derived from a single clone from the parent tumour and has to date appeared stable in vitro. This 
is advantageous as a molecular tool for genetic manipulation of candidate genes, but has the disadvantage of not 
offering insight into the heterogeneity of OAC. More complex models that recapitulate the complexity of OAC 
in vivo, such as primary xenografts or spheroids, will be required to address this issue. In addition, MFD-1 was 
derived from a particularly aggressive tumour and is the only cell line to be developed in our laboratory from 
several attempts (> 10). This highlights the difficulty in performing research in OAC with the currently available 
pre-clinical models that may not be representative of tumours seen in the clinic. However, MFD-1 does contain 
mutations that have been observed in commonly mutated genes in OAC from large, contemporary cohorts3,4,21 
and this is reassuring that MFD-1 has relevance for future research.
In summary, we describe a pre-clinical model system developed from the oesophageal ICGC project. The 
availability of genome and transcriptome wide data from the parent tumour and cell line makes MFD-1 perhaps 
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the best-catalogued OAC cell line in existence. Future OAC researchers will have confidence in the integrity of 
work performed with this cell line and will be able to easily confirm the significance of genetic changes in MFD-1 
by reference to the parent tumour by examination of the WGS data. Research in OAC is held back due to a lack of 
hi-fidelity pre-clinical models and further efforts should be directed to bridge this technology gap.
References
1. Noble, F. et al. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus. World J. Gastroenterol. 
19, 9282–9293 (2013).
2. Vaughan, T. L. & Fitzgerald, R. C. Precision prevention of oesophageal adenocarcinoma. Nature reviews. Gastroenterology & 
hepatology 12, 243–248, doi: 10.1038/nrgastro.2015.24 (2015).
3. Dulak, A. M. et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and 
mutational complexity. Nat. Genet. 45, 478–486 (2013).
4. Weaver, J. M. et al. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat. Genet. 46, 837–843 (2014).
5. Nones, K. et al. Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nat Commun 5, 
5224, doi: 10.1038/ncomms6224 (2014).
6. Murugaesu, N. et al. Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy. Cancer 
discovery 5, 821–831, doi: 10.1158/2159-8290.cd-15-0412 (2015).
7. Boonstra, J. J., Tilanus, H. W. & Dinjens, W. N. Translational research on esophageal adenocarcinoma: from cell line to clinic. Dis.
Esophagus. 28, 90–96 (2015).
8. Rubio, C. A. et al. Mucous gland metaplasia in the esophagus and gastric mucosa in baboons. Anticancer Res. 31, 2187–2190 (2011).
9. Attwood, S. E., Harrison, L. A., Preston, S. L. & Jankowski, J. A. Esophageal adenocarcinoma in “mice and men”: back to basics! Am. 
J. Gastroenterol. 103, 2367–2372 (2008).
10. Garman, K. S., Orlando, R. C. & Chen, X. Review: Experimental models for Barrett’s esophagus and esophageal adenocarcinoma. 
Am. J. Physiol Gastrointest. Liver Physiol 302, G1231–G1243 (2012).
11. Boonstra, J. J. et al. Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. J. Natl. Cancer Inst. 
102, 271–274 (2010).
12. Gillet, J.-P. et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug 
resistance. Proceedings of the National Academy of Sciences of the United States of America 108, 18708–18713, doi: 10.1073/
pnas.1111840108 (2011).
13. Zhang, X. et al. Malignant transformation of non-neoplastic Barrett’s epithelial cells through well-defined genetic manipulations. 
PLoS. One. 5 (2010).
14. Clemons, N. J. et al. Characterization of a novel tumorigenic esophageal adenocarcinoma cell line: OANC1. Dig. Dis. Sci. 59, 78–88 
(2014).
15. Underwood, T. J. et al. Cancer Associated Fibroblasts Predict for Poor Outcome and Promote Periostin-Dependent Invasion in 
Oesophageal Adenocarcinoma. The Journal of pathology, doi: 10.1002/path.4467 (2014).
16. Leedham, S. J. et al. Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett’s 
oesophagus. Gut 57, 1041–1048 (2008).
17. Edge, S. B. & Compton, C. C. The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and 
the Future of TNM. Annals of Surgical Oncology 17, 1471–1474, doi: 10.1245/s10434-010-0985-4 (2010).
18. Mandard, A. M. et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. 
Clinicopathologic correlations. Cancer 73, 2680–2686 (1994).
19. Korn, J. M. et al. Integrated genotype calling and association analysis of SNPs, common copy number polymorphisms and rare 
CNVs. Nat. Genet. 40, 1253–1260 (2008).
20. Greenman, C. D. et al. PICNIC: an algorithm to predict absolute allelic copy number variation with microarray cancer data. 
Biostatistics. 11, 164–175 (2010).
21. Weaver, J. M., Ross-Innes, C. S. & Fitzgerald, R. C. The ‘-omics’ revolution and oesophageal adenocarcinoma. Nature reviews. 
Gastroenterology & hepatology 11, 19–27, doi: 10.1038/nrgastro.2013.150 (2014).
22. Christoforides, A. et al. Identification of somatic mutations in cancer through Bayesian-based analysis of sequenced genome pairs. 
BMC.Genomics 14, 302 (2013).
23. Cingolani, P. et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the 
genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly. (Austin.) 6, 80–92 (2012).
24. Boeva, V. et al. Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. 
Bioinformatics 28, 423–425, doi: 10.1093/bioinformatics/btr670 (2012).
25. Trapnell, C. et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nature 
protocols 7, 562–578, doi: 10.1038/nprot.2012.016 (2012).
26. Anders, S., Pyl, P. T. & Huber, W. HTSeq–a Python framework to work with high-throughput sequencing data. Bioinformatics 
(Oxford, England) 31, 166–169, doi: 10.1093/bioinformatics/btu638 (2015).
27. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene 
expression data. Bioinformatics (Oxford, England) 26, 139–140, doi: 10.1093/bioinformatics/btp616 (2010).
28. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114–2120, 
doi: 10.1093/bioinformatics/btu170 (2014).
29. Reid, L. C. Cloning. Methods in enzymology 58, 152–164 (1979).
30. Underwood, T. J. et al. A comparison of primary oesophageal squamous epithelial cells with HET-1A in organotypic culture. Biol.
Cell 102, 635–644 (2010).
31. Moutasim, K. A., Nystrom, M. L. & Thomas, G. J. Cell migration and invasion assays. Methods Mol. Biol. 731, 333–343 (2011).
32. Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y. & Greenleaf, W. J. Transposition of native chromatin for fast and sensitive 
epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat Methods 10, 1213–1218, doi: 
10.1038/nmeth.2688 (2013).
33. Buenrostro, J. D., Wu, B., Chang, H. Y. & Greenleaf, W. J. ATAC-seq: A Method for Assaying Chromatin Accessibility Genome-
Wide. Curr Protoc Mol Biol 109, 21.29.21-29, doi: 10.1002/0471142727.mb2129s109 (2015).
34. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat Methods 9, 357–359, doi: 10.1038/nmeth.1923 (2012).
35. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079, doi: 10.1093/bioinformatics/btp352 
(2009).
36. Consortium, E. P. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57–74, doi: 10.1038/nature11247 
(2012).
37. Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol 9, R137, doi: 10.1186/gb-2008-9-9-r137 (2008).
38. Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for 
macrophage and B cell identities. Mol Cell 38, 576–589, doi: 10.1016/j.molcel.2010.05.004 (2010).
www.nature.com/scientificreports/
1 1Scientific RepoRts | 6:32417 | DOI: 10.1038/srep32417
39. Krzywinski, M. et al. Circos: An information aesthetic for comparative genomics. Genome Research 19, 1639–1645, doi: 10.1101/
gr.092759.109 (2009).
40. Chin, L., Andersen, J. N. & Futreal, P. A. Cancer genomics: from discovery science to personalized medicine. Nature medicine 17, 
297–303, doi: 10.1038/nm.2323 (2011).
41. Johnson, J. I. et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. British 
journal of cancer 84, 1424–1431, doi: 10.1054/bjoc.2001.1796 (2001).
42. Liu, X. et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. The American journal of 
pathology 180, 599–607, doi: 10.1016/j.ajpath.2011.10.036 (2012).
43. Onion, D. et al. Three-Dimensional, Humanised Tumour Growth Assays with Low Passage Tumours Provide a Tumour 
Microenvironment -Relevant Screen for Novel Chemotherapeutics. NC3Rs workshop: Understanding target-to-function biology in 
non-clinical oncology research (2014).
44. van de Wetering, M. et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161, 933–945, doi: 
10.1016/j.cell.2015.03.053 (2015).
45. Visonneau, S., Cesano, A., Torosian, M. H., Miller, E. J. & Santoli, D. Growth characteristics and metastatic properties of human 
breast cancer xenografts in immunodeficient mice. The American journal of pathology 152, 1299–1311 (1998).
46. Jin, K. et al. Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. Clinical & translational 
oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 12, 
473–480, doi: 10.1007/s12094-010-0540-6 (2010).
47. McKenzie, A. et al. In vivo response and molecular characterisation of a NSCLC squamous cell carcinoma PDX model exhibiting 
reproducible sensitivity to FGFR inhibitors. Cancer Research 73, 342–342, doi: 10.1158/1538-7445.am2013-342 (2013).
48. McKenzie, A. et al. In vivo generation of EGFR-TKI resistance in a patient-derived xenograft (PDX) with an activating EGFR 
mutation (L858R), and molecular characterisation of resistance mechanisms. Cancer Research 73, doi: 10.1158/1538-7445.am2013-
5651 (2013).
49. Rockett, J. C., Larkin, K., Darnton, S. J., Morris, A. G. & Matthews, H. R. Five newly established oesophageal carcinoma cell lines: 
phenotypic and immunological characterization. British journal of cancer 75, 258–263, doi: 10.1038/bjc.1997.42 (1997).
50. Shukla, S., Ohnuma, S. & Ambudkar, S. V. Improving cancer chemotherapy with modulators of ABC drug transporters. Curr Drug 
Targets 12, 621–630 (2011).
51. Purohit, A., Sadanandam, A., Myneni, P. & Singh, R. K. Semaphorin 5A mediated cellular navigation: connecting nervous system 
and cancer. Biochim Biophys Acta 1846, 485–493, doi: 10.1016/j.bbcan.2014.09.006 (2014).
Acknowledgements
The authors gratefully acknowledge funding from Cancer Research UK for the OCCAMS/ICGC project, MRC 
Clinician Scientist Grant for TJU, MCRC CRUK clinical training fellowship for EB, Maria Secrier for her advice 
regarding the WGS data and Southampton ECMC Tissue Bank and the Southampton Computation modelling 
group for access to the IRIDIS4 computer resource. We thank the Human Research Tissue Bank, University of 
Southampton and the Human Research Tissue Bank supported by the NIHR Cambridge Biomedical Research 
Centre, from Addenbrooke’s Hospital and UCL. Also the University Hospital of Southampton Trust and the 
Southampton, Birmingham, Edinburgh and UCL Experimental Cancer Medicine Centres and the QEHB 
charities. We are grateful to all patients who provided written consent for participation in this study and the staff 
at all participating centres.
Author Contributions
Conceived and designed the experiments: T.J.U., A.D.S., Y.A. and R.C.F. Performed the experiments: E.G., A.H., 
C.B., A.C., K.P., M.M., C.C., M.D., P.D. and M.J.W. Contributed reagent/materials: J.C.S. and R.C.F., OCCAMS 
Contributed with analysis tools: E.G., E.B., J.C.S., M.R.Z., A.D.S. and R.C.F. OCCAMS prepare figures: E.G., A.H., 
C.C., E.B. and T.J.U. All Authors reviewed the manuscript.
Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Garcia, E. et al. Authentication and characterisation of a new oesophageal 
adenocarcinoma cell line: MFD-1. Sci. Rep. 6, 32417; doi: 10.1038/srep32417 (2016).
This work is licensed under a Creative Commons Attribution 4.0 International License. The images 
or other third party material in this article are included in the article’s Creative Commons license, 
unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, 
users will need to obtain permission from the license holder to reproduce the material. To view a copy of this 
license, visit http://creativecommons.org/licenses/by/4.0/
 
© The Author(s) 2016
www.nature.com/scientificreports/
1 2Scientific RepoRts | 6:32417 | DOI: 10.1038/srep32417
OCCAMS consortium
Shona MacRae3, Nicola Grehan3, Zarah Abdullahi3, Rachel de la Rue3, Ayesha Noorani3, 
Rachael Fels Elliott3, Nadeera de Silva3, Jan Bornschein3, Maria O’Donovan3,  
Gianmarco Contino3, Tsun-Po Yang3, Hamza Chettouh3, Jason Crawte3, Barbara Nutzinger3,  
Paul A. W. Edwards3, Laura Smith3, Ahmad Miremadi4, Shalini Malhotra4, Alison Cluroe4, 
Richard Hardwick5, Jim Davies6, Hugo Ford7, David Gilligan7, Peter Safranek7,  
Andy Hindmarsh7, Vijayendran Sujendran7, Nick Carroll7, Richard Turkington8,  
Stephen J. Hayes9,15, Yeng Ang9,10,32, Shaun R. Preston11, Sarah Oakes11, Izhar Bagwan11, 
Vicki Save12, Richard J. E. Skipworth12, Ted R. Hupp12, J. Robert O’Neill12,25, Olga Tucker13,31, 
Philippe Taniere13, Jack Owsley14, Charles Crichton16, Christian Schusterreiter16,  
Hugh Barr17, Neil Shepherd17, Oliver Old17, Jesper Lagergren18,26,27, James Gossage18,26, 
Andrew Davies18,26, Fuju Chang18,26, Janine Zylstra18,26, Grant Sanders19, Richard Berrisford19, 
Catherine Harden19, David Bunting19, Mike Lewis20, Ed Cheong20, Bhaskar Kumar20,  
Simon L. Parsons21, Irshad Soomro21, Philip Kaye21, John Saunders21, Laurence Lovat22, 
Rehan Haidry22, Victor Eneh22, Laszlo Igali23, Ian Welch24, Michael Scott24, Shamila Sothi28, 
Sari Suortamo28, Suzy Lishman29, Duncan Beardsmore30, Charlotte Anderson33,  
Mike L. Smith33, Maria Secrier33, Matthew D. Eldridge33, Lawrence Bower33,  
Achilleas Achilleos33, Andy G. Lynch33 & Simon Tavare33
4Department of Histopathology, Addenbrooke’s Hospital, Cambridge, UK. 5Oesophago-Gastric Unit, Addenbrooke’s 
Hospital, Cambridge, UK. 6Oxford ComLab, University of Oxford, UK. 7Cambridge University Hospitals NHS 
Foundation Trust, Cambridge, UK. 8Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Northern 
Ireland, UK. 9Salford Royal NHS Foundation Trust, Salford, UK. 10Wigan and Leigh NHS Foundation Trust, Wigan, 
Manchester, UK. 11Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK. 12Edinburgh Royal Infirmary, 
Edinburgh, UK. 13University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. 14University Hospital 
Southampton NHS Foundation Trust, Southampton, UK. 15Faculty of Medical and Human Sciences, University 
of Manchester, UK. 16Department of Computer Science, University of Oxford, UK. 17Gloucester royal Hospital, 
Gloucester, UK. 18St Sharrocks’s Hospital, London, UK. 19Plymouth Hospitals NHS Trust, Plymouth, UK. 20Norfolk 
and Norwich University Hospital NHS Foundation Trust, Norwich, UK. 21Nottingham University Hospitals NHS Trust, 
Nottingham, UK. 22University College London, London, UK. 23Norfolk and Waveney Cellular Pathology Network, 
Norwich, UK. 24Wythenshawe Hospital, Manchester, UK. 25Edinburgh University, Edinburgh, UK. 26King’s College 
London, London, UK. 27Karolinska Institutet, Stockholm, Sweden. 28University Hospitals Coventry and Warwickshire 
NHS, Trust, Coventry, UK. 29Peterborough Hospitals NHS Trust, Peterborough City Hospital, Peterborough, UK. 
30Royal Stoke University Hospital, UHNM NHS Trust, UK. 31Institute of cancer and genomic sciences, University 
of Birmingham. 32GI science centre, University of Manchester, UK. 33Cancer Research UK Cambridge Institute, 
University of Cambridge, Cambridge, UK.
